Question 1

What is ATOLTIVIMAB used for?

Accepted Answer

ATOLTIVIMAB (brand name Inmazeb) is a Other indicated for 1 INDICATIONS AND USAGE INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2), and Clinical Studies (14) ] . INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab.

Question 2

How does ATOLTIVIMAB work?

Accepted Answer

ATOLTIVIMAB works through the following mechanism: 12.1 Mechanism of Action INMAZEB is an antiviral drug combination of three recombinant human IgG1κ monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Orthoebolavirus zairense [ see Microbiology (12.4) ]..

Question 3

What are the most common side effects of ATOLTIVIMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ATOLTIVIMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is ATOLTIVIMAB the same as Inmazeb?

Accepted Answer

Inmazeb is a brand name for ATOLTIVIMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ATOLTIVIMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations